METABOLISM
https://doi.org/10.12737/article_5955e6b426dd01.77009002
Abstract
According to the World Health Organization experts, the prevalence of diabetes is ahead of the most pessimistic forecasts and has already acquired the character of non-infectious epidemic in the world. Furthermore, today there is a tendency not only to the increase in the incidence of type 2 diabetes, but to the prevalence of comorbid conditions, including osteoporosis and osteopenia. In turn, in recent decades, osteoporosis is one of the most widespread and socially significant diseases, in all countries without exception its frequency in recent decades has been steadily increasing particularly among postmenopausal women. At the same time, a special state of bone metabolism in patients with type 2 diabetes is marked. The paper presents the study results of the content of the markers of bone metabolism in postmenopausal women with type 2 diabetes. Twenty-eight women, 15 of them with type 2 diabetes and 13 - in the control group were examined. The levels of ionized calcium, 25-OH vitamin D, osteocalcin, N-terminal propeptide of type 1 procollagen C-terminal telopeptides of type I collagen were determined. We also estimated the average daily calcium intake in women with type 2 diabetes. A substantial reduction in markers of bone metabolism, reflecting fixation processes, due to lower markers characterizing osteoresorption in patients with type 2 diabetes relative to the control group was determined. The findings raise the question of further studies of the mechanisms of formation of bone metabolism disorders in conditions of hyperglycemia.
About the Authors
T. P. Bardymova
Irkutsk State Medical Academy of Postgraduate Education - Branch Campus of the Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
M. V. Mistyakov
Irkutsk Municipal Polyclinic № 4
Russian Federation
Russian Federation
O. V. Seurko
Irkutsk State Medical Academy of Postgraduate Education - Branch Campus of the Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
References
1. Колесникова Л.И., Бардымова Т.П., Петрова В.А., Долгих М.И., Даренская М.А., Гребёнкина Л.А., Натяганова Л.В. Этнические особенности липидного и углеводного обменов у больных сахарным диабетом 1 типа // Бюллетень ВСНЦ СО РАМН. - 2006. - № 1. -С. 127-130.
2. Лесняк О.М. Аудит состояния проблемы остеопороза в странах восточной Европы и Центральной Азии 2010 // Остеопороз и остеопатии. - 2011. -№ 2. - С. 3-6.
3. Мокрышева Н.Г., Рожинская Л.Я. Современный взгляд на эффективность терапии постменопаузального остеопороза. Инновационные препараты таргетной терапии // Остеопороз и остеопатии. -2013. - № 1. - С. 29-33.
4. Рожинская Л.Я. Современные стратегии профилактики и лечения постменопаузального остеопороза // Медицинский совет. - 2012. - № 7. - С. 20-23.
5. Barrera G., Bunout D., Gattas V., de la Maza M.P., Leiva L., Hirsch S. (2004). A high body mass index protects against femoral neck osteoporosis in healthy elderly subjects. Nutrition, 20 (9), 769-771.
6. Body J.J., Bergmann P., Boonen S., Boutsen Y., Devogelaer J.P., Goemaere S., Kaufman J.M., Rozenberg S., Reginster J.Y. (2005). Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis Int., 16 (3), 1657-1680.
7. Dresner-Pollak R., Parker R.A., Poku M., Thompson J., Seibel M.J., Greenspan S.L. (1996). Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcified Tissue Int., 59 (5), 328-333.
8. Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P.D. (1999). Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY Study. J. Bone Miner. Res., 14 (9), 1614-1621.
9. Hansen M.A., Overgaard K., Riis B.J., Christiansen C. (1991). Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12-year study. BMJ, (303), 961-964.
10. IDF. Diabetes atlas. Available at: http://www.idf.org/sites/default/files/attachments/Atlas-poster-RU.pdf (date of access 01.10.2016).
11. Rosen C.J., Bouxsein M.L. (2006). Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol., 2 (1), 35-43.
12. Ross P., Knowlton W. (1998). Rapid bone loss is associated with increased levels of biochemical markers. J. Bone Miner. Res., 13 (2), 297-302.
13. Schousboe J.T., Bauer D.C., Nyman J.A., Kane R.L., Melton L.J., Ensrud K.E. (2006). Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporosis Int., 18 (2), 201-210.
14. Vestergaard P. (2007). Discrepancies in bone mineral density and fracture risk in patients with type
15. and type2 diabetes - a meta-analysis. Osteoporos Int., 18 (4), 427-444.
16. Yoshizawa T. (2016). Osteocalcin and osteonetwork. Clin. Calcium, 26 (8), 1149-1156.
Review
For citations:
Bardymova T.P., Mistyakov M.V., Seurko O.V. METABOLISM. Acta Biomedica Scientifica. 2017;2(1):16-18. (In Russ.) https://doi.org/10.12737/article_5955e6b426dd01.77009002
Views:
846
.png)
Email this article 
